Get the Stockscreener App
4.54
1.11%
0.05
After Hours:
4.53
-0.010
-0.22%
Cibus Inc stock is traded at $4.54, with a volume of 70,180.
It is up +1.11% in the last 24 hours and up +15.52% over the past month.
Cibus Inc is a biotechnology company. The company develops and commercializes a proprietary gene-editing technology, Rapid Trait Development System that integrates crop specific cell biology platforms with a series of gene editing technologies. The company's primary business is the development of plant traits that help address specific productivity or yield challenges in farming such as traits addressing plant agronomy, disease, insects, weeds, nutrient-use, or the climate.
See More
Previous Close:
$4.49
Open:
$4.5
24h Volume:
70,180
Relative Volume:
0.34
Market Cap:
$121.56M
Revenue:
$1.82M
Net Income/Loss:
$-267.63M
P/E Ratio:
-0.2522
EPS:
-18
Net Cash Flow:
$-50.53M
1W Performance:
+14.36%
1M Performance:
+15.52%
6M Performance:
-70.79%
1Y Performance:
-61.94%
1-Day Range:
$4.43
$4.79
1-Week Range:
$3.94
$4.8399
52-Week Range:
$2.858
$23.18
Cibus Inc Stock (CBUS) Company Profile
Name
Cibus Inc
Sector
Industry
Phone
(858) 450-0008
Address
6455 NANCY RIDGE DRIVE, SAN DIEGO
Compare CBUS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CBUS
Cibus Inc
|
4.54 | 121.56M | 1.82M | -267.63M | -50.53M | -18.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
464.56 | 119.70B | 10.63B | -479.80M | -1.35B | 13.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.87 | 82.75B | 13.85B | 4.65B | 3.32B | 35.06 |
|
ARGX
Argen X Se Adr
|
614.59 | 36.73B | 1.86B | -40.29M | -1.28B | -4.16 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.74 | 32.53B | 2.09B | -332.26M | 16.06M | -4.14 |
|
BNTX
Biontech Se Adr
|
120.72 | 28.50B | 3.30B | -501.07M | 1.03B | 11.54 |
Cibus Inc Stock (CBUS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-29-24 | Initiated | Alliance Global Partners | Buy |
| Jul-19-24 | Resumed | Canaccord Genuity | Buy |
| Oct-09-23 | Initiated | H.C. Wainwright | Buy |
| Jul-19-23 | Resumed | Canaccord Genuity | Buy |
Cibus Inc Stock (CBUS) Latest News
Cibus director sells $5,255 in company stock By Investing.com - Investing.com Canada
Cibus director sells $5,255 in company stock - Investing.com
Cibus director Prante sells shares worth $4,818 - Investing.com
Cibus stock outlook hinges on acreage expansion as Jefferies lowers target - Investing.com UK
Cibus director Prante Gerhard sells shares valued at $4,968 - Investing.com
Cibus director Prante Gerhard sells $9,579 in stock By Investing.com - Investing.com Nigeria
Cibus director Prante Gerhard sells $9,579 in stock - Investing.com India
Cibus director Gerhard Prante sells $9,947 in stock - Investing.com India
Cibus director Gerhard Prante sells $9,947 in stock By Investing.com - Investing.com UK
Cibus and Biographica Form Collaboration Using AI to Advance Disease Resistance in Canola and Oilseed Rape - CropLife
Cibus and Biographica Announce Collaboration Using Artificial Intelligence (AI) to Advance Disease Resistance in Canola and Oilseed Rape - The Manila Times
Cibus Partners with Biographica to Develop AI-Powered Disease-Resistant Crops | CBUS Stock News - StockTitan
Cibus Enhances Board with Appointment of August Moretti - TipRanks
Cibus to Participate in the 13th Annual Roth Technology Conference - The Manila Times
Cibus CEO to Present at Roth Technology Conference in NYC | Agricultural Tech Leader | CBUS Stock News - StockTitan
Cibus Achieves Additional Milestone for Next Generation Gene Edits for Sclerotinia Resistance in Canola - CropLife
Cibus interim CFO Broos Carlo sells shares worth $24,629 By Investing.com - Investing.com Australia
Cibus Achieves Additional Milestone for Next Generation Gene Edits for Sclerotinia Resistance ... - Leader-Telegram
Cibus Achieves Key Gene Editing Milestone in Canola Disease Resistance Program | CBUS Stock News - StockTitan
HC Wainwright Analysts Decrease Earnings Estimates for Cibus - Defense World
Cibus interim CFO Broos Carlo sells shares worth $24,629 - Investing.com
HC Wainwright Comments on Cibus' Q4 Earnings (NASDAQ:CBUS) - MarketBeat
Cibus (NASDAQ:CBUS) Earns Buy Rating from HC Wainwright - MarketBeat
What Analysts Are Saying About Cibus Stock - Benzinga
Cibus, Inc. (NASDAQ:CBUS) Q3 2024 Earnings Call Transcript - Insider Monkey
Cibus Inc (CBUS) Q3 2024 Earnings Call Highlights: Navigating Ch - GuruFocus.com
Cibus Inc (CBUS) Q3 2024 Earnings Call Highlights: Navigating Challenges and Seizing ... - Yahoo Finance
Cibus Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Cibus, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Cibus Reports Strategic Shift and Financial Update - TipRanks
Cibus: Q3 Earnings Snapshot - San Francisco Chronicle
Q3 2024 Cibus Inc Earnings Call Transcript - GuruFocus.com
Cibus Reports Third Quarter Financial Results and Provides Year-to-Date Business Update for 2024 - The Manila Times
Cibus Inc (CBUS) Q3 2024 Earnings Report Preview: What To Expect - GuruFocus.com
CBUSCibus, Inc. Latest Stock News & Market Updates - StockTitan
Cibus Confirms HT2 Trait Shows Increased Tolerance to a Novel Herbicide for Weed Control in Canola - CropLife
Cibus Confirms its Herbicide Tolerance (HT2) Trait Shows Increased Tolerance to a Novel Herbicide for Weed Control in Canola - ForexTV.com
Cibus Breakthrough: New Herbicide-Resistant Canola Trait Shows Promise in Key Tests | CBUS Stock News - StockTitan
Cellectis Provides Business Updates and Financial Results for Third Quarter 2024 - GlobeNewswire
Cibus (CBUS) Set to Announce Earnings on Thursday - MarketBeat
Cibus, Inc. (NASDAQ:CBUS) Short Interest Update - MarketBeat
Cibus to Report Third Quarter 2024 Financial Results on November 7, 2024 After the Market Close and Host Conference Call - StockTitan
Cibus to Report Third Quarter 2024 Financial Results on November 7, 2024 After the Market Close ... - Leader-Telegram
Cibus to Report Third Quarter 2024 Financial Results on November 7, 2024 After the Market Close and Host Conference Call - GlobeNewswire Inc.
Cibus (NASDAQ:CBUS) Receives “Buy” Rating from Canaccord Genuity Group - Defense World
Analyst Ratings For Cibus - Benzinga
Canaccord retains Buy rating on Cibus shares, cites royalty revenue - Investing.com India
Canaccord Genuity Group Reaffirms "Buy" Rating for Cibus (NASDAQ:CBUS) - MarketBeat
Cibus announces $10 million cost savings from restructuring By Investing.com - Investing.com Australia
Cibus announces $10 million cost savings from restructuring - Investing.com
Cibus Inc Stock (CBUS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):